Overview

• RAP-219 cut median clinical seizure frequency by about 78% over eight weeks, with 24% of participants experiencing seizure freedom during that period.
• An implanted-device biomarker of seizure activity known as long episodes fell by a median of 71%, corroborating the clinical reports.
• The mid-stage study enrolled roughly 30 people with drug-resistant focal onset seizures, most already taking two or three antiseizure medicines.
• No serious adverse events were reported; three participants discontinued for mild or moderate issues including a panic attack and worsening memory or anxiety.
• Rapport said it will seek an FDA end-of-Phase 2 meeting in Q4 2025, start a long-term safety study by year-end, and launch two Phase 3 trials in Q3 2026 as shares jumped up to about 194% and the company’s value topped $1 billion.